Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Ingelheim To Channel €100 Million Into Shanghai To Expand Production, Strengthen Quality Controls On APIs From China

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Germany's Boehringer Ingelheim recently announced it would funnel a new €100 million ($ 150 million) investment into China to increase production capacity at its plant in the Shanghai Zhangjiang Hi-Tech Park and to introduce state-of-the-art quality control technology for active pharmaceutical ingredients sourced from China

You may also be interested in...



Where’s The Beef? China Pushes For More Stringent Controls On Veterinary Drugs

A draft proposal by the Ministry of Agriculture comes at a time when several Big Pharma are pursuing opportunities in China’s veterinary market.

Boehringer Ingelheim Opens R&D Center In Shanghai; Sees Sales Growth From Products On NDRL Reimbursement List

SHANGHAI - Boehringer Ingelheim, the largest family-controlled pharma company, recently announced the opening of its Center of Competence in Shanghai. During the past year, the company invested €10 million to build the R&D center, which specializes in optimizing active pharmaceutical ingredients and chemical intermediates procured in China

Boehringer Ingelheim Opens R&D Center In Shanghai; Sees Sales Growth From Products On NDRL Reimbursement List

SHANGHAI - Boehringer Ingelheim, the largest family-controlled pharma company, recently announced the opening of its Center of Competence in Shanghai. During the past year, the company invested €10 million to build the R&D center, which specializes in optimizing active pharmaceutical ingredients and chemical intermediates procured in China

Related Content

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel